The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms

Netherlands Journal of Medicine

Volumn 73, Issue 9, 2015, Pages 417-431

  Willemse, S B ^a   Razavi Shearer, D ^b   Zuure, F R ^a,c   Veldhuijzen, I K ^d   Croes, E A ^e   van der Meer, A J ^f   van Santen, D K ^c   de Vree, J M ^g   de Knegt, R J ^f   Zaaijer, H L ^h   Reesink, H W ^a   Prins, M ^a,c   Razavi, H ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Center for Disease Analysis   (United States)

^c DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^d Rotterdam Rijnmond Public Health Service   (Netherlands)

^e NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h SANQUIN RESEARCH   (Netherlands)

Author keywords

HCV disease burden; HCV epidemiology; HCV treatment; Prediction model; The Netherlands

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD TRANSFUSION REACTION; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; FIBROSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MODEL; NETHERLANDS; PRACTICE GUIDELINE; PREVALENCE; REINFECTION; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SERODIAGNOSIS; SYSTEMATIC REVIEW; VALIDATION PROCESS; VIRAL CLEARANCE; VIREMIA; ADOLESCENT; ADULT; AGED; COST OF ILLNESS; FEMALE; HEPATITIS C, CHRONIC; MALE; MIDDLE AGED; MONTE CARLO METHOD; STATISTICAL MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COST OF ILLNESS; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MONTE CARLO METHOD; NETHERLANDS; PREVALENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84947577735     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Saito I, Miyamura T, Ohbayashi A, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA. 1990;87:6547-9.
2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45-57.
3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-128.
4. Wedemeyer H, Duberg AS, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21 Suppl 1:60-89.
5. Deuffic-Burban S, Deltenre P, Buti M, et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology. 2012;143:974-85.
6. Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat. 2014;21 Suppl 1:34-59.
7. World Health Organization. Global policy report on the prevention and control of viral hepatitis. Jan 2013. Available from URL: http://apps.who.int/iris/bitstream/10665/85397/1/9789241564632_eng.pdf.
8. World Health Organization. World health assembly adopts resolution on hepatitis. May 24, 2014. Available from URL: http://apps.who.int/gb/ ebwha/pdf_files/WHA67/A67_R6-eng.pdf.
9. Vriend HJ, Van Veen MG, Prins M, Urbanus AT, Boot HJ, Op de Coul EL. Hepatitis C virus prevalence in The Netherlands: migrants account for most infections. Epidemiol Infect. 2013;141:1310-7.
10. Vriend HJ, Op de Coul EL, van de Laar TJ, Urbanus AT, van der Klis FR, Boot HJ. Hepatitis C virus seroprevalence in The Netherlands. Eur J Public Health. 2012;22:819-21.
11. Slavenburg S, Verduyn-Lunel FM, Hermsen JT, Melchers WJ, te Morsche RH, Drenth JP. Prevalence of hepatitis C in the general population in the Netherlands. Neth J Med. 2008;66:13-7.
12. Veldhuijzen IK, Conyn-van Spaendonck MAE, Dorigo-Zetsma JW. Seroprevalentie van hepatitis B en C in de Nederlandse bevolking. Infectieziekten Bull. 1999;10:182-4.
13. Baaten GG, Sonder GJ, Dukers NH, Coutinho RA, Van den Hoek JA. Population-based study on the seroprevalence of hepatitis A, B, and C virus infection in Amsterdam, 2004. J Med Virol. 2007;79:1802-10.
14. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34-41.
15. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9:383-98.
16. Vermeiren AP, Dukers-Muijrers NH, Van Loo IH, et al. Identification of hidden key hepatitis C populations: an evaluation of screening practices using mixed epidemiological methods. PLoS One. 2012;7:e51194.
17. Hatzakis A, Chulanov VP, Gadano AC. The present and future disease burden of hepatitis C virus (HCV) with today’s treatment paradigm – volume 2. J Viral Hepat. 2015;22 Suppl 1:26-45.
18. Saraswat V, Norris S, de Knegt RJ, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2. J Viral Hepat. 2015;22 Suppl 1:6-25.
19. Aleman S, Rahbin N, Weiland O, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57:230-6.
20. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293-30.
21. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777-82.
22. United Nations. World population prospects: The 2010 revision – Population database. 2011; Available from URL: https://esa.un.org/unpd/wpp/index.htm.
23. De Vries MJ, Te Rijdt B, Van Nieuwkerk CM. Genotype distribution amongst hepatitis C patients in The Netherlands. Neth J Med. 2006;64:109-13.
24. Chaves S, Widdowson MA, Bosman A. Surveillance of HCV infection in the Netherlands. Euro Surveill. 2003;8:108-13.
25. Virologische Weekstaten 2005-2010 and 2011-2015. http://www.rivm.nl/Onderwerpen/V/Virologische_weekstaten
26. Van Aar F, Koedijk FDH, Van den Broek IVF, et al. Seksuele overdraagbare aandoeningen, waaronder HIV, in Nederland in 2013. Infectieziekten Bulletin. 2013: October.
27. Van den Berg CH, Smit C, Bakker M, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol. 2007;22:183-93.
28. Vanhommerig JW, Stolte IG, Lambers FA, et al. Stabilizing incidence of hepatitis C infection among men who have sex with men in Amsterdam. J Acquir Immune Defic Syndr. 2014;66:e111-5.
29. Grady BP, Vanhommerig JW, Schinkel J, et al. Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. Eur J Gastroenterol Hepatol. 2012;24:1302-7.
30. Lambers FA, Prins M, Thomas X, et al.; MOSAIC (MSM Observational Study of Acute Infection with hepatitis C) study group. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS. 2011;25:F21-7.
31. Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57:2164-70.
32. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992;327:1899-905.
33. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29:908-14.
34. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatology. 2008;48:418-31.
35. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127:855-65.
36. Bernfort L, Sennfalt K, Reichard O. Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scand J Infect Dis. 2006;38:497-505.
37. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology. 1999;30:1318-24.
38. Eurotransplant. Eurotransplant Statistics - 2013. Jan 8, 2014. Available from: URL: www.eurotransplant.org/cms/mediaobject.php?file=year_20131.pdf.
39. Human Mortality Database. University of California, Berkeley, Max Planck Institute for Demographic Research. Jun 14, 2013. Available from: URL: www.mortality.org.
40. Kershenobich D, Razavi HA, Cooper CL, et al. Applying a system approach to forecast the total hepatitis C virus-infected population size: Model validation using US data. Liver Int. 2011;31 Suppl 2:4-17.
41. GIPdatabank. Aantal gebruikers 2009-2013 voor ATC-subgroep J05AB04: Ribavirine. Mar 7 2014; Available from: URL: www.gipdatabank.nl/ databank.asp.
42. GIPdatabank. Aantal gebruikers 2008-2012 voor ATC-subgroep J05AB04: Ribavirine. Nov 27 2013; Available from: URL: www.gipdatabank.nl/ databank.asp.
43. Evon DM, Verma A, Dougherty KA, et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci. 2007;52:3251-8.
44. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med. 2005;20:754-8.
45. North CS, Hong BA, Adewuyi SA, et al. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry. 2013;35:122-8.
46. Gane E, Kershenobich D, Sequin-Devaux M, et al. Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2. J Viral Hepat. 2015;22 Suppl 1:47-73.
47. Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584-93.
48. Martin NK, Foster GR, Vilar J, et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat. 2014; Epub ahead of print.
49. De Vos AS, Prins M, Kretzschmar ME. Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first? Addiction 2015; Epub ahead of print.
50. Lee MH, Yang HI, Lu SN, et al; R.E.V.E.A.L.-HCV Study Group. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469-77.
51. Smith BD, Morgan RL, Beckett GA, et al; Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61:1-32. Erratum in: MMWR Recomm Rep. 2012;61:886.
52. Zuure FR, Bouman J, Martens M, et al. Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands. Liver Int. 2013;33:727-738.
53. Richter C, Beest GT, Sancak I, et al. Hepatitis B prevalence in the Turkish population of Arnhem: implications for national screening policy? Epidemiol Infect. 2012;140:724-730.
54. Richter C, Ter Beest G, Gisolf EH, et al. Screening for chronic hepatitis B and C in migrants from Afghanistan, Iran, Iraq, the former Soviet Republics, and Vietnam in the Arnhem region, The Netherlands. Epidemiol Infect. 2014;142:2140-6.
55. Zuure FR, Davidovich U, Coutinho RA, et al. Using mass media and the Internet as tools to diagnose hepatitis C infections in the general population. Am J Prev Med. 2011;40;345-52.
56. Helsper CW, Van Essen GA, Bonten MJ, De Wit NJ. A support programme for primary care leads to substantial improvements in the effectiveness of a public hepatitis C campaign. Family Pract. 2010;27:328-32.
57. Grintjes K, Dofferhoff ASM, Stelma F, et al. Hepatitis C detection among migrants in Nijmegen, The Netherlands. Tijdschr Infect. 2014;9:126-33.
58. Zuure FR, Heijman T, Urbanus AT, Prins M, Kok G, Davidovich U. Reasons for compliance or noncompliance with advice to test for hepatitis C via an internet-mediated blood screening service: a qualitative study. BMC Public Health. 2011;11:293.
59. Hickman M, Martin N, Vickerman P, Hutchison S. Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue. J Viral Hepat. 2014;21:e167-8.